Update shared on04 Aug 2025
Fair value Increased 7.77%The notable increase in Mirion Technologies’ future P/E and simultaneous decline in net profit margin suggest higher valuation expectations despite weaker profitability, leading analysts to raise the price target from $20.60 to $22.20.
What's in the News
- Mirion Technologies raised full-year 2025 revenue growth guidance to 7.0%-9.0% (from 5.0%-7.0% prior), factoring in a foreign exchange and acquisition tailwind, but trimmed organic growth expectations due to weakness in Labs & Research and Dosimetry markets.
- Launched the Vital Platform, offering a unified software solution for real-time radiological instrument data integration and monitoring at nuclear power sites, with first application 'Vital Supervision' enhancing efficiency, compliance, security, and analytics.
- Announced a strategic partnership with Westinghouse Electric to provide digital Ex-core Nuclear Instrumentation Systems using Mirion’s proTK product line, targeting upgrades of legacy systems and minimizing operational disruptions for global PWRs.
- Mirion Medical unveiled several new products at the SNMMI Annual Meeting, including Graves Phantom for precise dosimetry, InstadoseVUE Beta wireless dosimeter, new portable radiation monitoring devices, and software innovations, reinforcing its focus on radiopharma and regulatory compliance.
- Mirion was dropped from multiple Russell Value indexes, including the Russell 2000, 2500, 3000, 3000E, and Small Cap Comp Value Benchmarks.
Valuation Changes
Summary of Valuation Changes for Mirion Technologies
- The Consensus Analyst Price Target has risen from $20.60 to $22.20.
- The Future P/E for Mirion Technologies has significantly risen from 57.87x to 88.69x.
- The Net Profit Margin for Mirion Technologies has significantly fallen from 8.98% to 6.14%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.